BELLUS Health Inc  

(Public, TSE:BLU)   Watch this stock  
Find more results for BLU
0.820
+0.020 (2.50%)
Apr 17 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.78 - 0.85
52 week 0.24 - 0.99
Open 0.85
Vol / Avg. 31,104.00/62,834.00
Mkt cap 38.89M
P/E     -
Div/yield     -
EPS -0.02
Shares 47.43M
Beta 1.69
Inst. own     -

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin 193.37% -573.11%
Operating margin 168.94% 197.26%
EBITD margin - -157.40%
Return on average assets 17.62% -66.83%
Return on average equity 44.05% -
Employees 9 -
CDP Score - -

Address

275 Armand-Frappier Blvd.
LAVAL, QC H7V 4A7
Canada
+1-450-6804500 (Phone)
+1-450-6804501 (Fax)

Website links

Description

BELLUS Health Inc. (BELLUS Health), is a development-focused healthcare company. BELLUS Health is focusing on products, which provides health solutions and address medical needs. The Company�s product portfolio includes two pharmaceutical drug candidates and one commercial stage nutraceutical product, which include KIACTA, BLU8499 and VIVIMIND. BELLUS Health� primary focus is on advancing KIACTA, a treatment for AA amyloidosis through a pivotal Phase III Confirmatory Study. In August 2013, BELLUS Health Inc. acquired Thallion Pharmaceuticals Inc.